Red Door Wealth Management LLC Acquires 388 Shares of Becton, Dickinson and Company (NYSE:BDX)

Red Door Wealth Management LLC grew its holdings in Becton, Dickinson and Company (NYSE:BDX) by 33.9% during the 4th quarter, HoldingsChannel.com reports. The firm owned 1,531 shares of the medical instruments supplier’s stock after buying an additional 388 shares during the quarter. Red Door Wealth Management LLC’s holdings in Becton, Dickinson and Company were worth $347,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Livelsberger Financial Advisory bought a new stake in shares of Becton, Dickinson and Company in the third quarter valued at approximately $26,000. Ashton Thomas Securities LLC bought a new stake in shares of Becton, Dickinson and Company in the third quarter valued at approximately $33,000. Tompkins Financial Corp raised its position in shares of Becton, Dickinson and Company by 44.2% in the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 46 shares during the period. Sound Income Strategies LLC raised its position in shares of Becton, Dickinson and Company by 35.8% in the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 44 shares during the period. Finally, Kennebec Savings Bank bought a new stake in Becton, Dickinson and Company during the 3rd quarter worth approximately $46,000. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

BDX stock opened at $243.69 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.17 and a quick ratio of 0.74. Becton, Dickinson and Company has a one year low of $218.75 and a one year high of $248.42. The stock has a market cap of $70.67 billion, a PE ratio of 41.02, a P/E/G ratio of 1.72 and a beta of 0.39. The firm has a 50 day simple moving average of $227.70 and a two-hundred day simple moving average of $232.88.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, topping analysts’ consensus estimates of $3.77 by $0.04. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The business had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. During the same quarter in the previous year, the company earned $3.42 EPS. The business’s quarterly revenue was up 6.9% compared to the same quarter last year. On average, analysts predict that Becton, Dickinson and Company will post 14.42 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 31st. Stockholders of record on Monday, December 9th were paid a $1.04 dividend. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. The ex-dividend date was Monday, December 9th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.71%. Becton, Dickinson and Company’s dividend payout ratio is 70.03%.

Insider Activity

In other Becton, Dickinson and Company news, EVP David Shan sold 500 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total transaction of $120,000.00. Following the completion of the sale, the executive vice president now owns 5,741 shares of the company’s stock, valued at $1,377,840. This represents a 8.01 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Shana Carol Neal sold 788 shares of the stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $235.00, for a total transaction of $185,180.00. Following the sale, the executive vice president now directly owns 16,201 shares of the company’s stock, valued at $3,807,235. The trade was a 4.64 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 9,844 shares of company stock valued at $2,210,716. Corporate insiders own 0.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on BDX shares. Evercore ISI upped their target price on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. StockNews.com lowered shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Finally, Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their target price for the stock from $255.00 to $275.00 in a report on Tuesday, October 1st. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $283.50.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.